B. Shao

发表

Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer.

M. Hung, B. Shao, Chia-Wei Li, 2018, American journal of cancer research.

Transferrin Functionization Elevates Transcytosis of Nanogranules across Epithelium by Triggering Polarity-Associated Transport Flow and Positive Cellular Feedback Loop.

B. Shao, Huiping Li, Qiang Zhang, 2019, ACS nano.

Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients.

B. Shao, Huiping Li, G. Song, 2017, Breast.

HER2 Phenotyping of CTCs By Peptide-Functionalized Nanoparticles As The Diagnostic Biomarkers of Anti-HER2 Treatment in Breast Cancer

B. Shao, Huiping Li, Ping Li, 2021 .

Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients

B. Shao, Huiping Li, Jianjun Yu, 2022, Journal of Translational Medicine.

Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis

H. Rugo, B. Shao, Huiping Li, 2022, Frontiers in Pharmacology.

Receptor Conversion between Primary Tumors and Distant Metastases in 121 Cases of Metastatic Breast Cancer

B. Shao, Huiping Li, L. Di, 2013 .

Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall

B. Shao, Huiping Li, G. Song, 2018, Medicine.

Combination versus sequential paclitaxel plus gemcitabine as first-line chemotherapy for women with metastatic breast cancer: a prospective randomized phase II study.

B. Shao, Huiping Li, G. Song, 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer.

Zhiyuan Hu, H. Rugo, B. Shao, 2018, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Plasma CAMK2A predicts chemotherapy resistance in metastatic triple negative breast cancer.

B. Shao, Huiping Li, L. Di, 2018, International journal of clinical and experimental pathology.

Decrease of peripheral blood CD8+/CD28-suppressor T cell followed by dentritic cells immunomodulation among metastatic breast cancer patients

B. Shao, Jun Ren, J. Jia, 2010 .

HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment

B. Shao, Huiping Li, Ling Zhu, 2022, Frontiers in Bioengineering and Biotechnology.

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer

B. Shao, Huiping Li, L. Di, 2022, Current oncology.

The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR+HER2− metastatic breast cancer: a retrospective study

B. Shao, Huiping Li, L. Di, 2022, Annals of translational medicine.

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer

B. Shao, Huiping Li, Z. Tong, 2022, BMC Medicine.

Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple‐negative breast cancer cohort

B. Shao, Huiping Li, Jianmin Wu, 2017, Cancer medicine.

Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors

B. Shao, Huiping Li, L. Di, 2022, Frontiers in Oncology.

DREAM Community. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial

Stephen R. Piccolo, Suleiman A. Khan, Luke N. Kumar, 2016 .

Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients

B. Shao, Z. Wang, H. Lyerly, 2013, Clinical and Translational Oncology.

No association of single nucleotide polymorphisms involved in GHRL and GHSR with cancer risk: a meta-analysis.

B. Shao, Yaoyao Hao, Shengjie Zhu, 2015, Cancer biomarkers : section A of Disease markers.

Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer

B. Shao, Huiping Li, G. Song, 2016, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis

B. Shao, Huiping Li, Wenfa Huang, 2019, Breast Cancer Research and Treatment.

Plasma PIK 3 CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer

Liu, X. Yi, H. Rugo, 2018 .

Abstract CT048: Biomarker analysis from a phase 1 study of palbociclib (PAL) plus letrozole (L) as first-line treatment for ER+/HER2– advanced breast cancer (ABC) in Chinese women

Bing-he Xu, B. Shao, Huiping Li, 2018, Clinical Trials.

Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing.

M. Hung, B. Shao, Lin-lin Sun, 2018, American journal of cancer research.

Integrated analysis identifies an immune-based prognostic signature for the mesenchymal identity in colorectal cancer

B. Shao, Peng Shu, Zhixian Liu, 2020, Medicine.

Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer

B. Shao, Huiping Li, Xiaoxia Wang, 2019, Technology in cancer research & treatment.

Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study

Huan Wang, B. Shao, Huiping Li, 2023, Breast Cancer Research and Treatment.

The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis

B. Shao, Huiping Li, Hanfang Jiang, 2021, Anti-cancer drugs.

Deglycosylation of PD-L 1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer

M. Hung, B. Shao, Seung-Oe Lim, 2018 .

Methylome Variation Predicts Exemestane Resistance in Advanced ER+ Breast Cancer

H. Rugo, B. Shao, Huiping Li, 2020, Technology in cancer research & treatment.

Peptide-Functionalized Nanomaterials for the Efficient Isolation of HER2-Positive Circulating Tumor Cells.

B. Shao, Huiping Li, Chen Wang, 2017, ACS applied materials & interfaces.

Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors

H. Rugo, B. Shao, Huiping Li, 2020, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients

H. Yao, F. Su, E. Song, 2018, Nature Communications.

Clinical outcomes with first-line chemotherapy versus endocrine therapy for adjuvant endocrine therapy-resistant metastatic breast cancer

B. Shao, Huiping Li, Jinrong Qu, 2018, Translational Cancer Research.

Prognostic factors for patients with metastatic breast cancer: a literature review

B. Shao, Huiping Li, R. Ran, 2021, Translational cancer research.

Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbead-Assisted Flow Cytometry Detection of Tumor-Derived Extracellular Vesicles

B. Shao, Huiping Li, Chen Wang, 2018, Small Methods.

PD-L1-Mediated Gasdermin C Expression Switches Apoptosis to Pyroptosis in Cancer Cells and Facilitates Tumor Necrosis

J. Tainer, M. Hung, B. Shao, 2020, Nature Cell Biology.

Author Correction: PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis

J. Tainer, L. Nie, M. Hung, 2020, Nature Cell Biology.

Clinicopathological features and prognosis of patients with pregnancy‐associated breast cancer: A matched case control study

B. Shao, Huiping Li, L. Di, 2021, Asia-Pacific journal of clinical oncology.

Bilateral breast cancer in China: A 10‐year single‐center retrospective study (2006–2016)

B. Shao, Huiping Li, L. Di, 2021, Cancer medicine.

Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study

B. Shao, Wei Li, Yixuan Qiu, 2021, Frontiers in Oncology.

Combined Let-7a and H19 Signature: A Prognostic Index of Progression-Free Survival in Primary Breast Cancer Patients

F. Yu, F. Su, B. Shao, 2018, Journal of breast cancer.

A lymph node metastasis‐related protein‐coding genes combining with long noncoding RNA signature for breast cancer survival prediction

B. Shao, Chunyan Ju, Yujie Sui, 2019, Journal of cellular physiology.

A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients

H. Yao, F. Su, E. Song, 2018, Nature Communications.

Palbociclib plus letrozole as first-line treatment for ER-positive and HER2-negative advanced breast cancer in Chinese women: a phase 1 study

Bing-he Xu, B. Shao, Huiping Li, 2017 .

Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting

B. Shao, Huiping Li, A. Zhu, 2023, Frontiers in Oncology.

Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2‐ metastatic breast cancer: A single center real‐world study in China

B. Shao, Huiping Li, Hanfang Jiang, 2024, Cancer medicine.

Persistence of peripheral CD8 + CD28− T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer

B. Shao, Huiping Li, S. Jia, 2024, British journal of cancer.

Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer

B. Shao, Huiping Li, S. Jia, 2024, Breast cancer research and treatment.